By Chris Wack
BWX Technologies Inc. said its BWXT Medical Ltd. subsidiary has entered into a new long-term, mutually exclusive agreement to manufacture TheraSphere Y-90 Glass Microspheres for Boston Scientific.
The company said TheraSphere was developed for the treatment of patients with hepatocellular carcinoma, and is comprised of millions of glass microspheres containing radioactive Yttrium-90, which are delivered directly to liver tumors via catheter and result in minimal exposure to surrounding healthy tissue.
Under the terms of the agreement, BWXT Medical will invest to automate the production process at its Ottawa, Canada, facility, and significantly increase capacity and dependability to support a growing global demand for TheraSphere.
BWXT said Boston Scientific recently received Food and Drug Administration PMA approval of TheraSphere, which expands patient access for this technology.
Write to Chris Wack at email@example.com
(END) Dow Jones Newswires
May 10, 2021 07:10 ET (11:10 GMT)Copyright (c) 2021 Dow Jones & Company, Inc.